Covidien (NYSE: COV, BSX: COV), a leading global provider of
healthcare products, today announced that its Energy-based Devices
business unit has introduced LigaSure Advance(TM), the first
multifunctional laparoscopic instrument that offers surgeons fingertip
control of both tissue fusion and monopolar dissection.
LigaSure Advance(TM) was created in response to what surgeons said
they need to optimize efficiency and safety in the operating room.
This latest innovation in the LigaSure(TM) lineup is a 5 mm
hand-activated instrument that provides surgeons with the ability to
create fusion cycles in two to four seconds, and when used with
Valleylab(TM) mode, the unique energy modality delivers dissection and
hemostasis.
With sterile-field control of mode and power settings, LigaSure
Advance(TM) is designed to enable surgeons and perioperative staff to
focus more effectively on the procedure and patient. Its versatility
reduces the need for instrument exchanges, making procedures more
efficient and potentially reducing overall operating time.
"My initial impression when I used the LigaSure Advance(TM) in
laparoscopic colon surgery centered on versatility," said Morris E.
Franklin Jr., M.D., Texas Endosurgery Institute, San Antonio, Texas.
"Having both LigaSure(TM) and monopolar capabilities in one instrument
significantly reduces surgical time, as less time is lost changing
between instruments."
LigaSure Advance(TM) is for use exclusively with the
ForceTriad(TM) energy platform controlled by TissueFect(TM) sensing
technology, which in one unit supplies the operating room with
enhanced monopolar, bipolar and tissue fusion energy.
"We found the LigaSure Advance(TM) to be far faster and more
effective than conventional clamp and tie methods," said Todd
Heniford, M.D., Carolinas Medical Center, Charlotte, N.C. "For bowel
mesentery resections, the added benefit of an incorporated dissecting
electrode may lead to reduced operative time and less hand fatigue."
"We are excited to introduce this innovative surgical instrument
to the marketplace. We are confident it better serves the needs of our
customers and further advances patient care," said Bryan Hanson
President, Energy-based Devices, Covidien. "The launch of the LigaSure
Advance(TM) instrument once again reflects Covidien´s continuing
commitment to be a leading provider of first-in-class electrosurgical
devices."
ABOUT COVIDIEN
Covidien is a leading global healthcare products company that
creates innovative medical solutions for better patient outcomes and
delivers value through clinical leadership and excellence. Covidien
manufactures, distributes and services a diverse range of
industry-leading product lines in four segments: Medical Devices
Imaging Solutions, Pharmaceutical Products and Medical Supplies. With
2007 revenue of nearly $9 billion, Covidien has more than 43,000
employees worldwide in 57 countries, and its products are sold in over
130 countries. Please visit www.covidien.com to learn more about our
business.
